Pfizer and BioNTech have applied to the US Food and Drug Administration to use their improved Covid-19 vaccine as the third dose in a three-dose primary vaccination series for children aged 6 months to 4 years.

If the vaccine is approved for emergency use, children in that age range will still receive the old Covid-19 vaccination as their first two doses, followed by the revised Covid-19 vaccine developed to target the coronavirus Omicron subvariants BA.4 and BA.5.

While the core Covid-19 vaccine series for older children and adults consists of two doses of the Pfizer/BioNTech vaccine, children under the age of five have received a three-dose primary series.

Read More

KRDO Rating

Share this:

Leave a Reply